Ionis Pharmaceuticals Inc (NASDAQ:IONS) Expected to Post Quarterly Sales of $140.79 Million

Share on StockTwits

Wall Street brokerages forecast that Ionis Pharmaceuticals Inc (NASDAQ:IONS) will report sales of $140.79 million for the current quarter, according to Zacks. Five analysts have provided estimates for Ionis Pharmaceuticals’ earnings, with the highest sales estimate coming in at $158.44 million and the lowest estimate coming in at $126.00 million. Ionis Pharmaceuticals posted sales of $117.75 million in the same quarter last year, which suggests a positive year-over-year growth rate of 19.6%. The company is expected to issue its next earnings results on Tuesday, August 6th.

According to Zacks, analysts expect that Ionis Pharmaceuticals will report full-year sales of $777.39 million for the current fiscal year, with estimates ranging from $715.00 million to $934.00 million. For the next fiscal year, analysts anticipate that the company will report sales of $961.96 million, with estimates ranging from $653.96 million to $1.81 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Ionis Pharmaceuticals.

Ionis Pharmaceuticals (NASDAQ:IONS) last released its earnings results on Thursday, May 9th. The company reported $0.62 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.43 by $0.19. The company had revenue of $297.00 million for the quarter, compared to the consensus estimate of $285.43 million. Ionis Pharmaceuticals had a return on equity of 44.03% and a net margin of 47.74%. Ionis Pharmaceuticals’s quarterly revenue was up 106.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.01) earnings per share.

Several research firms recently weighed in on IONS. Cantor Fitzgerald began coverage on Ionis Pharmaceuticals in a research report on Tuesday, April 9th. They set a “neutral” rating and a $68.00 target price on the stock. Piper Jaffray Companies set a $75.00 target price on Ionis Pharmaceuticals and gave the company a “neutral” rating in a research report on Friday, March 22nd. BMO Capital Markets lifted their target price on Ionis Pharmaceuticals to $96.00 and gave the company an “outperform” rating in a research report on Monday, April 22nd. Finally, Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “buy” rating and set a $93.00 target price on the stock in a research report on Thursday, April 18th. Eight investment analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $68.25.

NASDAQ IONS traded down $0.51 on Friday, hitting $65.08. 16,458 shares of the company traded hands, compared to its average volume of 1,208,619. The firm has a market cap of $9.28 billion, a P/E ratio of 21.91 and a beta of 2.10. The company has a quick ratio of 9.36, a current ratio of 9.40 and a debt-to-equity ratio of 0.47. The business has a 50 day simple moving average of $64.76. Ionis Pharmaceuticals has a 52-week low of $41.25 and a 52-week high of $86.58.

In other news, Director B Lynne Parshall sold 50,000 shares of the business’s stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $75.01, for a total value of $3,750,500.00. Following the transaction, the director now directly owns 102,677 shares in the company, valued at $7,701,801.77. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Chairman Stanley T. Crooke sold 32,000 shares of the business’s stock in a transaction dated Tuesday, April 16th. The shares were sold at an average price of $84.84, for a total value of $2,714,880.00. Following the completion of the transaction, the chairman now owns 79,634 shares in the company, valued at $6,756,148.56. The disclosure for this sale can be found here. Insiders sold 120,210 shares of company stock worth $8,995,724 over the last 90 days. Company insiders own 2.40% of the company’s stock.

Institutional investors have recently made changes to their positions in the company. Buffington Mohr McNeal purchased a new position in shares of Ionis Pharmaceuticals in the first quarter valued at about $28,000. First Interstate Bank purchased a new stake in shares of Ionis Pharmaceuticals in the first quarter worth about $34,000. Quadrant Capital Group LLC lifted its position in shares of Ionis Pharmaceuticals by 2,839.1% in the first quarter. Quadrant Capital Group LLC now owns 676 shares of the company’s stock worth $53,000 after buying an additional 653 shares in the last quarter. Carroll Financial Associates Inc. lifted its position in shares of Ionis Pharmaceuticals by 27.4% in the first quarter. Carroll Financial Associates Inc. now owns 762 shares of the company’s stock worth $61,000 after buying an additional 164 shares in the last quarter. Finally, Cullen Frost Bankers Inc. purchased a new stake in shares of Ionis Pharmaceuticals in the first quarter worth about $101,000. Institutional investors and hedge funds own 82.67% of the company’s stock.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

Featured Article: Lock-Up Period Expiration

Get a free copy of the Zacks research report on Ionis Pharmaceuticals (IONS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.